WASHINGTON (dpa-AFX) - AbbVie (ABBV) announced that a new 6-month 45mg LUPRON DEPOT, or leuprolide acetate for extended-release injectable suspension, strength has received Health Canada approval for the treatment of advanced prostate cancer. LUPRON DEPOT is now available in four dosing options.
LUPRON DEPOT is a hormonal medication approved by Health Canada for various conditions including advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. It is a synthetic gonadotropin-releasing hormone analog. LUPRON DEPOT was initially approved by Health Canada for advanced prostate cancer in 1989.
For More Such Health News, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
